Open AccessTreating rheumatoid arthritis with leflunomide monotherapy versus combination therapy with methotrexate
Author(s) -
Daniel Ampessan Guadagnin,
Leonardo Vinicius Mazzali,
Thelma Larocca Skare,
Bárbara Stadler Kahlow
Publication year - 2021
Publication title -
european journal of rheumatology :/european journal of rheumatology
Language(s) - English
Resource type - Journals
eISSN - 2147-9720
pISSN - 2148-4279
DOI - 10.5152/eurjrheum.2020.20113
Subject(s) - leflunomide , erythrocyte sedimentation rate , medicine , methotrexate , rheumatoid arthritis , combination therapy , creatinine , gastroenterology , arthritis , toxicity
Combination therapies have been proposed as a strategy to control inflammation more effectively in patients with rheumatoid arthritis (RA). Few studies examine the combined effect of methotrexate (MTX) and leflunomide (LFN). This study evaluated the symptom control and side effects of the combination of MTX and LFN compared with LFN monotherapy.